Adrenal Gland Tumor Diagnosis and Treatment Market: Overview
Adrenal glands are located on top of kidneys. The two primary types of adrenal gland tumors are adrenal cortical carcinoma and pheochromocytoma. Adrenal cortical carcinoma is cancer of adrenal cortex. Two types of tumor are associated with adrenal cortex: functioning tumor and non-functioning tumor. Functioning tumor is responsible for increase in the production of adrenal hormones, while non-functioning tumor does not affect hormonal production. Adrenal cortical carcinoma is generally a secondary type of cancer. It occurs when another form of cancer spreads to the adrenal glands. Pheochromocytoma occurs most frequently in adults aged between 30 and 60. It is not life-threatening, but has 10% chances of being cancerous. High blood pressure is the most common symptom; however, excessive sweating, light-headedness, a fast and pounding pulse when standing, severe headache, rapid breathing, and other symptoms could also occur. Factors such as unhealthy lifestyle habits such as smoking and drinking are contributing to growth of the adrenal gland tumor diagnosis and treatment market.
Adrenal Gland Tumor Diagnosis and Treatment Market: Segmentation
The global adrenal gland tumor diagnosis and treatment market can be segmented based on tumor type, treatment, test, end-user, and region. In terms of tumor type, the market can be categorized into pheochromocytoma, adrenal cortical carcinoma, and others (paragangliomas, etc.). Pheochromocytoma is an efficient catecholamine-secreting tumor of the adrenal gland medulla. Catecholamines include epinephrine, norepinephrine, and their derivatives. Symptoms of pheochromocytoma include elevated blood pressure, elevated heart rate, flank skin, anxiety, weight loss, sweating, and headache. Within normal limits, epinephrine and norepinephrine hormones are responsible for regulating the heart rate and blood pressure. Excess production of catecholamine due to pheochromocytoma is a reason for high blood pressure with life-threatening and potentially serious difficulties such as stroke and heart attack. Where adrenal cortical carcinoma forms in the outer layer of the gland that is involved in production of lifesaving hormones such as mineralocorticoids and glucocorticoids (aldosterone and cortisol) required for metabolism and stress management. Based on treatment, the global adrenal gland tumor diagnosis and treatment market can be classified into surgery, chemotherapy, radiotherapy, targeted cancer therapies, and others. In terms of test, the market can be divided into magnetic resonance imaging (MRI), computed tomography (CT) scan, X-ray, positron emission tomography (PET) scan, and biopsy. Based on end-user, the global adrenal gland tumor diagnosis and treatment market can be categorized into hospitals, ambulatory surgical centers, cancer centers, and others.
Adrenal Gland Tumor Diagnosis and Treatment Market: Regional Analysis
Geographically, the global adrenal gland tumor diagnosis and treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018 due to rapid changes in lifestyle and availability of better treatment options. According to the American Cancer Society, adrenal tumors (most of which are benign adenomas) are found in 1 in every 10 people who undergo tests such as CT scan or MRI of the adrenal gland. According to Clinical Key, a health care website by Elsevier, Inc., prevalence of adrenal tumor is estimated to be around 2 cases per 100,000 individuals in the U.S. every year. Around 5% of adrenal incidentalomas are pheochromocytomas. Studies have also shown that about 25% of these are hereditary. Hence, increase in expertise in gene therapy could help in curbing cancer growth.
Adrenal Gland Tumor Diagnosis and Treatment Market: Competitive Landscape
Key players in the global adrenal gland tumor diagnosis and treatment market are HRA Pharma, ER Squibb & Sons LLC, Bristol-Myers Squibb Company, GE Healthcare, WG Critical Care, LLC, David Bull Laboratories (Pty) Ltd., Mylan Pharmaceuticals, Fresenius Kabi, Pfizer, SINOVISION Technologies (Beijing) Co., Ltd., Hitachi Medical Systems, NeuroLogica Corp., and Digirad Corporation.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.